Restructuring hones Dainippon Sumitomo's pharma focus
This article was originally published in Scrip
Executive Summary
The board of Dainippon Sumitomo Pharma (DSP) in Japan has approved plans to spin out internally the group's animal health and food and speciality products businesses. The company is also ending a domestic co-marketing agreement for JCR Pharmaceuticals' growth hormone product.